Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PreTarg-it
- Development stage
- Preclinical
- Lead developer
- OncoOne
- Modality
- Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
PreTarg-it is a proprietary pretargeted radioimmunotherapy (PRIT) platform developed by OncoOne Research & Development for the treatment of solid tumors. The technology utilizes a two-step approach to deliver therapeutic radioisotopes directly to tumor cells while minimizing systemic exposure. In the first step, a bispecific antibody (bsAb) is administered, which binds to a specific tumor-associated antigen—most notably the oxidized form of Macrophage Migration Inhibitory Factor (oxMIF)—and provides a docking site for a radiolabeled payload. After the antibody has cleared from the circulation, a small-molecule radioligand is administered in the second step, which rapidly and specifically binds to the pre-localized antibody at the tumor site. This strategy is designed to overcome the limitations of conventional radioimmunotherapy, such as prolonged blood circulation of radiolabeled antibodies that can lead to dose-limiting bone marrow toxicity.
- Brand names
- PreTarg-it
- Other names
- PreTarg-it platform
02
Targets
MIF (Oxidized macrophage migration inhibitory factor)
Beyond the preview
Go deeper on PreTarg-it.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PreTarg-it.